skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment

Original Research

(2045) Views  (510) Full article downloads

Authors: Christopher Au-Yeung, Steve Kanters, Erin Ding, et al

Published Date January 2011 Volume 2011:3(1) Pages 21 - 29
DOI: http://dx.doi.org/10.2147/CLEP.S15574

Christopher Au-Yeung1, Steve Kanters1, Erin Ding1, Philippe Glaziou2, Aranka Anema1,3, Curtis L Cooper4, Julio SG Montaner1,3, Robert S Hogg1,5, Edward J Mills1,6
1BC Centre for Excellence in HIV/AIDS, Vancouver, Canada; 2Stop TB Department, World Health Organization, Geneva, Switzerland; 3Faculty of Medicine, University of British Columbia, Vancouver, Canada; 4The Ottawa Hospital Division of Infectious Diseases; 5Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada; 6Faculty of Health Sciences, University of Ottawa, Ottawa, Canada

Objective: Tuberculosis (TB) is a leading cause of death in human immunodeficiency virus (HIV)-positive individuals. We sought to compare mortality rates in TB/HIV co-infected individuals globally and by country/territory.
Design: We conducted a cross-national systematic assessment.
Methods: TB mortality rates in HIV-positive and HIV-negative individuals were obtained from the World Health Organization (WHO) Stop TB department for 212 recognized countries/territories in the years 2006–2008. Multivariate linear regression determined the impact of health care resource and economic variables on our outcome variable, and TB mortality rates.
Results: In 2008, an estimated 13 TB/HIV deaths occurred per 100,000 population globally with the African region having the highest death rate ([AFRH] ≥4% adult HIV-infection rate) at 86 per 100,000 individuals. The next highest rates were for the Eastern European Region (EEUR) and the Latin American Region (LAMR) at 4 and 3 respectively per 100,000 population. African countries’ HIV-positive TB mortality rates were 29.9 times higher than non-African countries (95% confidence interval [CI]: 16.8–53.4). Every US$100 of government per capita health expenditure was associated with a 33% (95% CI: 24%–42%) decrease in TB/HIV mortality rates. The multivariate model also accounted for calendar year and did not include highly active antiretroviral therapy (HAART) coverage.
Conclusions: Our results indicate that while the AFRH has the highest TB/HIV death rates, countries in EEUR and LAMR also have elevated mortality rates. Increasing health expenditure directed towards universal HAART access may reduce mortality from both diseases.

Keywords: tuberculosis, HIV, antiretroviral therapy, mortality




 

Other articles by Dr Edward Mills

Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patients
Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis
Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis
Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals
Multiple treatment comparison meta-analyses: a step forward into complexity
Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis
Stability of additive treatment effects in multiple treatment comparison meta-analysis: a simulation study


Readers of this article also read:

30-days mortality in patients with perforated peptic ulcer: A national audit
Medical complications in patients with stroke: data validity in a stroke registry and a hospital discharge registry
Medical databases in studies of drug teratogenicity: methodological issues
National Stroke Audit: The Australian experience
Identification of a reliable subset of process indicators for clinical audit in stroke care: an example from Australia
Epidemiology and treatment approaches in management of invasive fungal infections
Multiple treatment comparison meta-analyses: a step forward into complexity
Sudden cardiac death in young athletes
Flushing ports of totally implantable venous access devices, and impact of the Huber point needle bevel orientation: experimental tests and numerical computation
Stability of additive treatment effects in multiple treatment comparison meta-analysis: a simulation study